

DAFTAR PUSTAKA

1. Meledathu S, Naidu MP, Brunner PM. Update on atopic dermatitis. *Journal of Allergy and Clinical Immunology*. 2025 Apr;155(4):1124–32. doi:10.1016/j.jaci.2025.01.013
2. Jeskey J, Kurien C, Blunk H, Sehmi K, Areti S, Nguyen D, et al. Atopic Dermatitis: A Review of Diagnosis and Treatment. *The Journal of Pediatric Pharmacology and Therapeutics*. 2024 Dec 1;29(6):587–603. doi:10.5863/1551-6776-29.6.587
3. Paul C, Griffiths CEM, Costanzo A, Herranz P, Grond S, Mert C, et al. Factors Predicting Quality of Life Impairment in Adult Patients with Atopic Dermatitis: Results from a Patient Survey and Machine Learning Analysis. *Dermatol Ther (Heidelb)*. 2023 Apr 2;13(4):981–95. doi:10.1007/s13555-023-00897-0
4. Jamil W, Von Kobyletzki L, Berg M, Lindberg M. Dermatology Life Quality Index as a Prognostic Tool for Predicting Need for Healthcare in Patients with Eczema: A Pilot Study. *Acta Derm Venereol*. 2022 Mar 22;102:adv00673. doi:10.2340/actadv.v102.269
5. Arents BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, Flohr C. The future is now: the Global Atopic Dermatitis Atlas (GADA). *British Journal of Dermatology*. 2023 Nov 16;189(6):761–3. doi:10.1093/bjd/ljad286
6. Sun C, Zhang X, Su Z, Yao WH, Chen HD, Zeng YP. Global, regional, and national burdens of atopic dermatitis from 1990 to 2021: A trend analysis from the Global Burden of Disease Study 2021. *J Am Acad Dermatol*. 2025 Oct;93(4):1008–17. doi:10.1016/j.jaad.2025.06.042
7. Magnifico I, Petronio Petronio G, Venditti N, Cutuli MA, Pietrangelo L, Vergalito F, et al. Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy? *Pharmaceuticals*. 2020 Nov 22;13(11):411. doi:10.3390/ph13110411
8. Brown SJ, Elias MS, Bradley M. Genetics in Atopic Dermatitis: Historical Perspective and Future Prospects. *Acta Derm Venereol*. 2020 Jun 9;100(12):adv00163. doi:10.2340/00015555-3513 PubMed PMID: 32412647.
9. Luschkova D, Zeiser K, Ludwig A, Traidl-Hoffmann C. Atopic eczema is an environmental disease. *Allergol Select*. 2021 Jan 1;5(01):244–50. doi:10.5414/ALX02258E
10. Santamaria-Babi L. Atopic Dermatitis Pathogenesis: Lessons From Immunology. *Dermatol Pract Concept*. 2022 Feb 2;e2022152. doi:10.5826/dpc.1201a152
11. Torres T, Mendes-Bastos P, Cruz MJ, Duarte B, Filipe P, Lopes MJP, et al. Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review. *Dermatol Ther (Heidelb)*. 2025 Mar 10;15(3):579–97. doi:10.1007/s13555-025-01352-y
12. Napolitano M, di Vico F, Ruggiero A, Fabbrocini G, Patrino C. The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis. *Front Med (Lausanne)*. 2023 Apr 18;10. doi:10.3389/fmed.2023.1165098
13. Harvey J, Lax SJ, Lowe A, Santer M, Lawton S, Langan SM, et al. The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. *Skin health and disease*. 2023 Oct;3(5):e268. doi:10.1002/ski2.268 PubMed PMID: 37799373.
14. Łabędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. *Advances in Dermatology and Allergology*. 2019;36(6):752–9. doi:10.5114/ada.2019.91425
15. Daoud G, Ahsan F, Mahmood T, Bano S, Ansari VA, Zaidi SMH, et al. Therapeutic potential and bioactive compounds of *Apium graveolens*: A phytopharmacological review. *Pharmacological Research - Reports*. 2025 Mar;3:100039. doi:10.1016/j.prerep.2025.100039

16. Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, et al. The Therapeutic Potential of Apigenin. *Int J Mol Sci.* 2019 Mar 15;20(6):1305. doi:10.3390/ijms20061305
17. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Front Pharmacol.* 2014;4. doi:10.3389/fphar.2013.00177
18. Irizar A, Boislève F, Gautier F, Nash JF, Pfuhler S, Ritacco G, et al. Phototoxicity and skin damage: A review of adverse effects of some furocoumarins found in natural extracts. *Food and Chemical Toxicology.* 2025 Jun;200:115332. doi:10.1016/j.fct.2025.115332
19. Pate HF. Not as Bland as You May Think: Celery (*Apium graveolens*) Commonly Induces Phytophotodermatitis. *Cutis.* 2025 Mar 1;115(3). doi:10.12788/cutis.1199
20. Nasri H, Shirzad H. Toxicity and safety of medicinal plants. *J HerbMed Pharmacol.* 2013 Apr 1;2:21–2.
21. Han D, Row KH. Determination of luteolin and apigenin in celery using ultrasonic-assisted extraction based on aqueous solution of ionic liquid coupled with HPLC quantification. *J Sci Food Agric.* 2011 Dec 11;91(15):2888–92. doi:10.1002/jsfa.4553
22. Yoon JH, Kim MY, Cho JY. Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer. *Int J Mol Sci.* 2023 Jan 12;24(2):1498. doi:10.3390/ijms24021498
23. Che DN, Cho BO, Shin JY, Kang HJ, Kim JS, Oh H, et al. Apigenin Inhibits IL-31 Cytokine in Human Mast Cell and Mouse Skin Tissues. *Molecules.* 2019 Apr 2;24(7):1290. doi:10.3390/molecules24071290
24. Chen F, He D, Yan B. Apigenin Attenuates Allergic Responses of Ovalbumin-Induced Allergic Rhinitis Through Modulation of Th1/Th2 Responses in Experimental Mice. *Dose-Response.* 2020 Jan 1;18(1). doi:10.1177/1559325820904799
25. Meng X, Zheng S, Yin Z, Wang X, Yang D, Zou T, et al. Apigenin ameliorates imiquimod-induced psoriasis in C57BL/6J mice by inactivating STAT3 and NF-κB. *Food Science and Human Wellness.* 2024 Jan;13(1):211–24. doi:10.26599/FSHW.2022.9250018
26. Yano S, Umeda D, Yamashita S, Yamada K, Tachibana H. Dietary apigenin attenuates the development of atopic dermatitis-like skin lesions in NC/Nga mice. *J Nutr Biochem.* 2009 Nov;20(11):876–81. doi:10.1016/j.jnutbio.2008.08.002
27. Niu W, Li Y, Liu X, Miao M, Wang G, Wang N, et al. A Comparative Study on the Effects of Apigenin and Quercetin on the Activity of Dominant Bacteria in Atopic Dermatitis. 2023. doi:10.2139/ssrn.4347102
28. Man MQ, Hupe M, Sun R, Man G, Mauro TM, Elias PM. Topical Apigenin Alleviates Cutaneous Inflammation in Murine Models. *Evidence-Based Complementary and Alternative Medicine.* 2012;2012:1–7. doi:10.1155/2012/912028
29. Hou M, Sun R, Hupe M, Kim PL, Park K, Crumrine D, et al. Topical apigenin improves epidermal permeability barrier homeostasis in normal murine skin by divergent mechanisms. *Exp Dermatol.* 2013 Mar 12;22(3):210–5. doi:10.1111/exd.12102
30. Ruscinc N, Massarico Serafim RA, Almeida C, Rosado C, Baby AR. Challenging the safety and efficacy of topically applied chlorogenic acid, apigenin, kaempferol, and naringenin by HET-CAM, HPLC-TBARS-EVSC, and laser Doppler flowmetry. *Front Chem.* 2024 May 20;12. doi:10.3389/fchem.2024.1400881
31. Jin H, He R, Oyoshi M, Geha RS. Animal Models of Atopic Dermatitis. *Journal of Investigative Dermatology.* 2009 Jan;129(1):31–40. doi:10.1038/jid.2008.106
32. Riedl R, Kühn A, Hupfer Y, Hebecker B, Peltner LK, Jordan PM, et al. Characterization of Different Inflammatory Skin Conditions in a Mouse Model of DNCB-Induced Atopic Dermatitis. *Inflammation.* 2024 Apr 27;47(2):771–88. doi:10.1007/s10753-023-01943-x

33. Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index-A Practical Guide. *Dermatitis*. 33(3):187–92. doi:10.1097/DER.0000000000000895 PubMed PMID: 35594457.
34. Zhang Q, Wang H, Ran C, Lyu Y, Li F, Yao Y, et al. Anti-inflammatory effects of amarogentin on 2,4-dinitrochlorobenzene-induced atopic dermatitis-like mice and in HaCat cells. *Animal Model Exp Med*. 2023 Jun 21;6(3):255–65. doi:10.1002/ame2.12260
35. Dizon MP, Yu AM, Singh RK, Wan J, Chren MM, Flohr C, et al. Systematic review of atopic dermatitis disease definition in studies using routinely collected health data. *British Journal of Dermatology*. 2018 Jun;178(6):1280–7. doi:10.1111/bjd.16340
36. Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, et al. Nomenclature and clinical phenotypes of atopic dermatitis. *Ther Adv Chronic Dis*. 2021 Jan 26;12. doi:10.1177/20406223211002979
37. Tang X, Lin L, Yu F, Ma Y, Liu Z, Xu X. Allergic-related skin diseases: Global disease burden from 1990 to 2021 and future trends. *World Allergy Organization Journal*. 2025 Jul;18(7):101072. doi:10.1016/j.waojou.2025.101072
38. Lopez Carrera YI, Al Hammadi A, Huang YH, Llamado LJ, Mahgoub E, Tallman AM. Epidemiology, Diagnosis, and Treatment of Atopic Dermatitis in the Developing Countries of Asia, Africa, Latin America, and the Middle East: A Review. *Dermatol Ther (Heidelb)*. 2019 Dec 24;9(4):685–705. doi:10.1007/s13555-019-00332-3
39. Liu H, Dong H, Chen W, Li X, Xiao Z, Li H. Global, Regional, and National Burden of Atopic Dermatitis: Insights From the Global Burden of Disease Study 2021. *Dermatitis*. 2025 Aug 6. doi:10.1177/17103568251365559 PubMed PMID: 40765527.
40. Tsai T, Rajagopalan M, Chu C, Encarnacion L, Gerber RA, Santos-Estrella P, et al. Burden of atopic dermatitis in Asia. *J Dermatol*. 2019 Oct 22;46(10):825–34. doi:10.1111/1346-8138.15048
41. Sun C, Zhang X, Su Z, Yao WH, Chen HD, Zeng YP. Global, regional, and national burdens of atopic dermatitis from 1990 to 2021: A trend analysis from the Global Burden of Disease Study 2021. *J Am Acad Dermatol*. 2025 Oct;93(4):1008–17. doi:10.1016/j.jaad.2025.06.042
42. Weidinger S, Novak N. Atopic dermatitis. *The Lancet*. 2016 Mar;387(10023):1109–22. doi:10.1016/S0140-6736(15)00149-X
43. Brown SJ. Molecular mechanisms in atopic eczema: insights gained from genetic studies. *J Pathol*. 2017 Jan 14;241(2):140–5. doi:10.1002/path.4810
44. Lushkova D, Zeiser K, Ludwig A, Traidl-Hoffmann C. Atopic eczema is an environmental disease. *Allergol Select*. 2021;5:244–50. doi:10.5414/ALX02258E PubMed PMID: 34476334.
45. Lee SY, Lee E, Park YM, Hong SJ. Microbiome in the Gut-Skin Axis in Atopic Dermatitis. *Allergy Asthma Immunol Res*. 2018;10(4):354. doi:10.4168/aa.2018.10.4.354
46. Criado PR, Miot HA, Bueno-Filho R, Ianhez M, Criado RFJ, de Castro CCS. Update on the pathogenesis of atopic dermatitis. *An Bras Dermatol*. 2024 Nov;99(6):895–915. doi:10.1016/j.abd.2024.06.001
47. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. *Allergy Asthma Proc*. 2019 Mar 1;40(2):84–92. doi:10.2500/aap.2019.40.4202
48. Fan X, Liu Z, Yang W, Zhang H, Zhong H, Pang Y, et al. Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural Product-Based Therapies. *Phytotherapy Research*. 2025 Oct 19;39(10):4444–73. doi:10.1002/ptr.70056
49. Kim K, Kim H, Sung GY. An Interleukin-4 and Interleukin-13 Induced Atopic Dermatitis Human Skin Equivalent Model by a Skin-On-A-Chip. *Int J Mol Sci*. 2022 Feb 14;23(4):2116. doi:10.3390/ijms23042116

50. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. *Journal of Allergy and Clinical Immunology*. 2019 Jan;143(1):1–11. doi:10.1016/j.jaci.2018.10.032
51. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *New England Journal of Medicine*. 2016 Dec 15;375(24):2335–48. doi:10.1056/NEJMoa1610020
52. Nakatsuji T, Chen TH, Two AM, Chun KA, Narala S, Geha RS, et al. *Staphylococcus aureus* Exploits Epidermal Barrier Defects in Atopic Dermatitis to Trigger Cytokine Expression. *Journal of Investigative Dermatology*. 2016 Nov;136(11):2192–200. doi:10.1016/j.jid.2016.05.127
53. Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. *J Am Acad Dermatol*. 2019 Feb;80(2):390–401. doi:10.1016/j.jaad.2018.09.035
54. Chatrath S, Silverberg JI. Phenotypic differences of atopic dermatitis stratified by age. *JAAD Int*. 2023 Jun;11:1–7. doi:10.1016/j.jdin.2022.08.026
55. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment. *Exp Dermatol*. 2018 Apr 8;27(4):340–57. doi:10.1111/exd.13514
56. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018 Jun 21;4(1):1. doi:10.1038/s41572-018-0001-z
57. Lee JH, Lee SH, Bae Y, Lee YB, Jang YH, Ahn J, et al. 2023 Consensus Korean Diagnostic Criteria for Atopic Dermatitis. *Ann Dermatol*. 2025;37(1):12. doi:10.5021/ad.24.049
58. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *The Lancet*. 2020 Aug;396(10247):345–60. doi:10.1016/S0140-6736(20)31286-1
59. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. *Journal of the European Academy of Dermatology and Venereology*. 2020 Dec 17;34(12):2717–44. doi:10.1111/jdv.16892
60. Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. *Journal of Allergy and Clinical Immunology*. 2023 Dec;152(6):1493–519. doi:10.1016/j.jaci.2023.08.030
61. Braschi É, Young J, Allan GM. Topical corticosteroids for atopic dermatitis. *Canadian Family Physician*. 2024 Sep 13;70(9):558–558. doi:10.46747/cfp.7009558
62. Braschi É, Moe SS. Topical calcineurin inhibitors for atopic dermatitis. *Canadian Family Physician*. 2023 Nov 14;69(11):773–4. doi:10.46747/cfp.6911773
63. Abuhalmeh RM, Alghuyaythat WK, Altariqi SAA, Alghofaili JA, Alghweri HR, Alsaadi GMA, et al. Efficacy and Safety of Topical Difamilast in the Treatment of Atopic Dermatitis: A Systematic Review. *Saudi Medical Horizons Journal*. 2025 Aug 25;5(3):223–30. doi:10.54293/smhj.v5i3.163
64. Sharma K, Tharmatt A, Salooria S, Sharma R, Bedi N. Topical Corticosteroids in Treatment of Atopic Dermatitis: An Overview of Their Current Status. *J Pharm Res Int*. 2021 Jan 1;1–20. doi:10.9734/jpri/2020/v32i3831008
65. Feldman SR, Cox LS, Strowd LC, Gerber RA, Faulkner S, Sierka D, et al. The Challenge of Managing Atopic Dermatitis in the United States. *Am Health Drug Benefits*. 2019 Apr;12(2):83–93. PubMed PMID: 31057694.
66. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. *J Nutr Sci*. 2016;5:e47. doi:10.1017/jns.2016.41 PubMed PMID: 28620474.
67. Siddiquee R, Mahmood T, Ansari VA, Ahsan F, Bano S, Ahmad S. Apigenin unveiled: an encyclopedic review of its preclinical and clinical insights. *Discover Plants*. 2025 Jan 20;2(1):11. doi:10.1007/s44372-024-00039-6

68. Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, et al. The Therapeutic Potential of Apigenin. *Int J Mol Sci.* 2019 Mar 15;20(6). doi:10.3390/ijms20061305 PubMed PMID: 30875872.
69. Hostetler GL, Ralston RA, Schwartz SJ. Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity. *Advances in Nutrition.* 2017 May;8(3):423–35. doi:10.3945/an.116.012948
70. Singh A, Singh J, Parween G, Khator R, Monga V. A comprehensive review of apigenin a dietary flavonoid: biological sources, nutraceutical prospects, chemistry and pharmacological insights and health benefits. *Crit Rev Food Sci Nutr.* 2025 Aug 26;65(23):4529–65. doi:10.1080/10408398.2024.2390550
71. Shankar E, Goel A, Gupta K, Gupta S. Plant Flavone Apigenin: an Emerging Anticancer Agent. *Curr Pharmacol Rep.* 2017 Dec 14;3(6):423–46. doi:10.1007/s40495-017-0113-2
72. Cannataro R, Fazio A, La Torre C, Caroleo MC, Cione E. Polyphenols in the Mediterranean Diet: From Dietary Sources to microRNA Modulation. *Antioxidants.* 2021 Feb 23;10(2):328. doi:10.3390/antiox10020328
73. Li MY, Hou XL, Wang F, Tan GF, Xu ZS, Xiong AS. Advances in the research of celery, an important Apiaceae vegetable crop. *Crit Rev Biotechnol.* 2018 Feb 17;38(2):172–83. doi:10.1080/07388551.2017.1312275
74. Khairullah AR, Solikhah TI, Nur A, Ansori M, Hidayatullah AR, Hartadi EB, et al. Review on the Pharmacological and Health Aspects of *Apium Graveolens* or Celery: An Update. *Systematic Reviews in Pharmacy.* 2021.
75. Uddin Z, Shad A, Bakht J, Ullah I, Jan S. In vitro antimicrobial, antioxidant activity and phytochemical screening of *Apium graveolens*. *Pak J Pharm Sci.* 2015 Sep 26;28:1699–704.
76. Yano S, Umeda D, Maeda N, Fujimura Y, Yamada K, Tachibana H. Dietary Apigenin Suppresses IgE and Inflammatory Cytokines Production in C57BL/6N Mice. *J Agric Food Chem.* 2006 Jul 1;54(14):5203–7. doi:10.1021/jf0607361

